12 Mar, 2025
4 mins read

Voyager Therapeutics Announces Setback In SOD1 ALS Gene Therapy Program

Voyager Therapeutics, a company that specializes in bioinformatics, has announced a significant update to its gene therapy program for superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS). The company informed on Tuesday, February 11, 2025, that it would be experimenting with other main deliveries for its SOD1 ALS gene therapy program due to the singular […]